Please Wait.....
Report
Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
Market Research Report I 2025-03-20 I 211 Pages I BCC Research
Description
Report Scope
Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.
Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions-North America, Europe, Asia-Pacific and the Rest of the World-as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.
Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:
- Lung.
- Breast.
- Liver.
- Stomach.
- Prostate.
- Colorectal.
- Gastric.
- Cervical.
- Bladder.
- Kidney.
- Ovarian.
- Lymphoma.
- Multiple myeloma.
- Brain tumors.
- Thyroid.
- Uterine.
Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.
For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.
Report Includes
- 51 data tables and 83 additional tables
- An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions
- Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region
- A look at the factors driving the market's growth and constraints
- Insight into the industry value chain analysis, providing a study of the intermediaries involved
- Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
- Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden
- Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation
- Identification of the fastest-growing applications and technologies, and a review of current market trends
- Discussion of the industry's ESG challenges and practices
- Review of the current market status, technology issues, industry value chain, Porter's Five Forces, competitive landscape, R&D activity and patent analysis
- Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
- Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments
- Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca
Executive Summary
Summary:
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
The global cancer therapeutics market emphasis on recurrent and metastatic divisions was valued at $108.1 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.7% to reach $168 billion by the end of 2029. There are several reasons why the oncology pharmaceutical sector is a promising one for growth. The dynamic and quickly changing oncology pharmaceutical market is a part of the global pharmaceutical industry. The development, manufacturing and distribution of medications used to treat cancer are the main objectives of this market, which is anticipated to keep expanding considering the continuous developments in science and technology. Novel immunotherapies and CAR-T cell therapy are two emerging treatments that could completely change the way cancer is treated. The accessibility and affordability of medications must be addressed to ensure that new treatments benefit a wide range of patients.
The movement of cancer cells from their original locations to different areas of the body is known as "metastasis" or "metastatic cancer." Cancer cells separate from the original tumor during metastasis, move through the blood or lymphatic system and develop into a new tumor in different body tissues or organs. The primary tumor and the new metastatic tumor are the same type of cancer. Breast cancer cells, not lung cancer cells, are present in the lung if the disease spreads there.
Compared to localized cancers, metastatic cancer usually has a worse prognosis, and it is more challenging to treat. Given the aggressive nature of metastatic disease and the difficulty of overcoming resistance to current therapies, there is a significant need for novel treatments for metastatic cancers, making this market crucial. There are more metastatic cases due to patients living longer after initial treatment due to advances in cancer detection and treatment. Approximately 90% of cancer-related deaths are thought to be caused by metastases (Chaffer CL et al., Science, 2011). With the advent of combination therapies, which combine immunotherapy, targeted therapy and chemotherapy to boost efficacy and overcome resistance, the market for treatments for metastatic cancer is rapidly changing.
Genetic profiling and biomarker testing enable treatments specific to each patient's cancer type and mutations, so personalized medicine is increasingly playing a crucial role in the treatment of metastatic cancers.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Metastatic or Recurrent Cancer Treatment Types
Surgery
Chemotherapy
Radiotherapy
Targeted Therapy
Cancer Immunotherapies
Oncolytic Virotherapy
Antibody-Drug Conjugates
Porter's Five Forces Analysis in the Oncology Market
Potential of New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Industry Rivalry: High
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Robust Approval of Oncology Drugs
Technological Advances in Cancer Treatments
Increasing Incidence of Cancer Disease
Market Restraints
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
Market Opportunities
Incorporation of Artificial Intelligence in Oncology
Promising Drugs in the Late Stage of the Pipeline
Chapter 4 Regulatory Landscape
The U.S. Approval Process
FDA Regulatory Considerations for Oncology Drug Development
European Union Approval Process
Current Situation in E.U. Approval Process
Japanese Approval Process
Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Technologies
Personalized Cancer Vaccines
Test to Identify 18 Early-Stage Cancers
CAR T-Cell Therapy
Artificial Intelligence
Tablet to Cut Breast Cancer Risk
Nanoparticles
Pressurized Intraperitoneal Aerosol Chemotherapy
Cervical Cancer Treatment Breakthrough
New Developments
Biosimilar Approvals
Pipeline Analysis
Clinical Trial Analysis
Patent Analysis
Key Takeaways
Chapter 6 Supply Chain Analysis
Overview
Research and Development
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Cancer Drug Shortage
Costs
Manufacturing Complexity
Geographic Concentration
Quality
Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Liver Cancer
Cervix Cancer
Bladder Cancer
Kidney Cancer
Pancreatic Cancer
Ovarian Cancer
All Other Cancers
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Competitive Intelligence
Overview
Blockbuster Oncology Pharmaceutical Brands
Global Market Shares of Leading Companies
Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental Factors
Social Issues
Governance Factors
ESG Risk Ratings
Conclusion
Chapter 10 Appendix
Methodology
Emerging Start-ups/Market Disruptors
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
List of Tables
Summary Table : Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 1 : Typical Various Metastatic Cancer Treatments
Table 2 : Promising Drugs in Late Stage of Pipeline, 2023
Table 3 : FDA Drug Approvals in Oncology, 2021?2023
Table 4 : Oncology Drug Approvals, 2020?July 2024
Table 5 : Novel Oncology Drug Approvals for Relapsed or Metastatic Cancers, 2021?November 2024*
Table 6 : FDA Approved Biosimilar for Oncology Indications, 2015?2024
Table 7 : FDA Approved Biosimilars and Interchangeable Biosimilars, by FDA, July 2024
Table 8 : EMA Approved Biosimilar for Oncology Indications, 2007?July 2024
Table 9 : Clinical Trial Drugs for Metastatic Cancers in Phases 3 and 4, 2024
Table 10 : Granted Patents in Metastatic Cancer Field, 2022?2024
Table 11 : Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 12 : Clinical Trial Study for Metastatic Lung Cancer, 2024
Table 13 : Global Market for Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 14 : Common Drugs Used to Treat Metastatic Breast Cancer, 2023
Table 15 : Clinical Trial Studies for Metastatic Breast Cancer, 2024
Table 16 : Global Market for Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 17 : Clinical Trial Study for Metastatic Colorectal Cancer, 2024
Table 18 : Global Market for Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 19 : Clinical Trial Study for Metastatic Prostate Cancer, 2024
Table 20 : Global Market for Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 21 : Clinical Trial Study for Metastatic Stomach Cancer, 2024
Table 22 : Global Market for Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 23 : Clinical Trial Study for Metastatic Liver Cancer, 2024
Table 24 : Global Market for Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 25 : Clinical Trial Study for Metastatic Cervical Cancer, 2024
Table 26 : Global Market for Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 27 : Clinical Trial Study for Metastatic Bladder Cancer, 2024
Table 28 : Global Market for Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 29 : Clinical Trial Study for Metastatic Kidney Cancer, 2024
Table 30 : Global Market for Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 31 : Clinical Trial Study for Metastatic Pancreatic Cancer, 2024
Table 32 : Global Market for Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 33 : Clinical Trial Study for Metastatic Ovarian Cancer, 2024
Table 34 : Global Market for Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 35 : Global Market for All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 36 : Global Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 37 : North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 38 : North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 39 : Incidence and Mortality of Cancer Cases in the U.S., Both Sexes, 2024
Table 40 : U.S. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 41 : Canadian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 42 : Incidence and Mortality of Cancer Cases in Mexico, Both Sexes, 2022
Table 43 : Mexican Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 44 : European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 45 : European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 46 : Incidence and Mortality of Cancer Cases in Germany, Both Sexes, 2022
Table 47 : German Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 48 : U.K. New Diagnosed Cancer Cases, 2021 and 2022
Table 49 : U.K. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 50 : Cancer Incidence and Mortality Cases in Franch, Both Sexes, 2022
Table 51 : French Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 52 : Cancer Incidence and Mortality Cases in Spain, Both Sexes, 2022
Table 53 : Spanish Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 54 : Cancer Incidence and Mortality Cases in Italy, Both Sexes, 2022
Table 55 : Italian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 56 : Rest of the European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 57 : Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 58 : Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 59 : Cancer Incidence and Mortality in China, Both Sexes, 2022
Table 60 : Chinese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 61 : Japanese Cancer Incidence and Mortality, Both Sexes, 2022
Table 62 : Japanese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 63 : Cancer Incidence and Mortality Cases in India, Both Sexes, 2022
Table 64 : Indian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 65 : Cancer Incidence and Mortality Cases in South Korea, Both Sexes, 2022
Table 66 : South Korean Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 67 : Rest of Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 68 : Rest of World Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 69 : Drug Pipeline for Major Companies for Metastatic or Relapsed Condition, 2023
Table 70 : ESG Risk Rankings for Oncology Pharmaceuticals Companies, Through January 2025
Table 71 : List of a Few Emerging Startups
Table 72 : Report Information Sources
Table 73 : Abbreviations Used in the Global Cancer Therapeutics Market with Emphasis on Recurrent and Metastatic Divisions
Table 74 : AbbVie Inc.: Company Snapshot
Table 75 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 76 : AbbVie Inc.: Product Portfolio
Table 77 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 78 : Amgen Inc.: Company Snapshot
Table 79 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 80 : Amgen Inc.: Product Portfolio
Table 81 : Amgen Inc.: News/Key Developments, 2022-2024
Table 82 : AstraZeneca: Company Snapshot
Table 83 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 84 : AstraZeneca: Product Portfolio
Table 85 : AstraZeneca: News/Recent Developments, 2022?2024
Table 86 : Bayer AG: Company Snapshot
Table 87 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 88 : Bayer AG: Product Portfolio
Table 89 : Bayer AG: News/Key Developments, 2023-2024
Table 90 : Bristol-Myers Squibb Co.: Company Snapshot
Table 91 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 92 : Bristol-Myers Squibb Co.: Product Portfolio
Table 93 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98 : Gilead Sciences Inc.: Company Snapshot
Table 99 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 100 : Gilead Sciences Inc.: Product Portfolio
Table 101 : Gilead Sciences Inc.: News/Key Developments, 2022?2024
Table 102 : Johnson & Johnson Services Inc.: Company Snapshot
Table 103 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 104 : Johnson & Johnson Services Inc.: Product Portfolio
Table 105 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 106 : Lilly: Company Snapshot
Table 107 : Lilly: Financial Performance, FY 2022 and 2023
Table 108 : Lilly: Product Portfolio
Table 109 : Lilly: News/Key Developments, 2023 and 2024
Table 110 : Merck & Co. Inc.: Company Snapshot
Table 111 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 112 : Merck & Co. Inc.: Product Portfolio
Table 113 : Merck & Co. Inc.: News/Key Developments, 2021-2024
Table 114 : Novartis AG: Company Snapshot
Table 115 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 116 : Novartis AG: Product Portfolio
Table 117 : Novartis AG: News/Key Developments, 2022-2024
Table 118 : Pfizer Inc.: Company Snapshot
Table 119 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 120 : Pfizer Inc.: Product Portfolio
Table 121 : Pfizer Inc.: News/Key Developments, 2021-2024
Table 122 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 123 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 124 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 125 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 126 : Sanofi: Company Snapshot
Table 127 : Sanofi: Financial Performance, FY 2022 and 2023
Table 128 : Sanofi: Product Portfolio
Table 129 : Sanofi: News/Key Developments, 2022-2024
Table 130 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 131 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 132 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 133 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2021-2024
List of Figures
Summary Figure : Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
Figure 1 : Porter's Five Forces Analysis of the Oncology Market
Figure 2 : Market Dynamics of the Global Cancer Therapeutics Market Emphasis on Recurrent and Metastatic Divisions
Figure 3 : Novel Oncology Drugs with FDA Approvals, 2016?2024
Figure 4 : U.S. Cancer Incidence, 2000?2021
Figure 5 : Share of Incidence Cases of All Cancer Types, Both Sexes, by WHO Region, 2022
Figure 6 : Oncology Drug Clinical Trial Studies, by Trial Phase, 2021?July 2024
Figure 7 : Phase 3 and 4 Clinical Trial Studies of Oncology Drugs for Metastatic and Recurrent Division, by Company, July 2024
Figure 8 : Top Applicants in Metastatic Cancer Patents, 2022?2024
Figure 9 : Supply Chain Process of Pharmaceutical Drugs
Figure 10 : Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
Figure 11 : Global Market Share of Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 12 : Global Market Share of Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 13 : Global Market Share of Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 14 : Global Market Share of Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 15 : Global Market Share of Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 16 : Global Market Share of Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 17 : Global Market Share of Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 18 : Global Market Share of Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 19 : Global Market Share of Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 20 : Global Market Share of Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 21 : Global Market Share of Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 22 : Global Market Share of All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 23 : Global Market Share of Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 24 : North American Market Share of Cancers Therapeutics Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 25 : Share of Cancer Incidence Cases in Europe, Both Sexes, by Cancer Type, 2022
Figure 26 : Share of Cancer Mortality Cases in Europe, Both Sexes, by Cancer Type, 2022
Figure 27 : European Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 28 : U.K. Current and Forecast Cancer Prevalence, 2020?2040
Figure 29 : Asia-Pacific and Oceania Share of Cancer Incidence, Both Sexes, 2022
Figure 30 : Asia-Pacific and Oceania Share of Cancer Mortality, Both Sexes, 2022
Figure 31 : Asia-Pacific Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 32 : Top 10 Blockbuster Oncology Pharmaceutical Drugs, by Sales Revenue, 2023
Figure 33 : Company Share Analysis of Oncology Pharmaceutical Manufacturers, 2023
Figure 34 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 38 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 39 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 40 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 41 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 42 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 43 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 44 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 45 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 46 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 47 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 48 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 49 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 50 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 51 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 52 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 53 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 54 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 55 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 56 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 57 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 58 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 59 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 60 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 61 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 62 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 63 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security